Relative Bioavailability of Telmisartan/Amlodipine Fixed-dose Combination Compared to Its Mono-components in Healthy Male Volunteers

Phase 1

Completed

• Conditions: Healthy
• Interventions: Drug: Telmisartan/amlodipine fixed-dose combination (FDC) tablet; Drug: Telmisartan; Drug: Amlodipine

• Registration Number: NCT02259803
• Lead Sponsor: Boehringer Ingelheim

Brief Summary

Study to investigate the relative bioavailability of fixed-dose combination tablet vs.

mono-components of telmisartan and amlodipine

Detailed Description

Not available

Study Timeline

• Study Start: 2007-10
• Primary Completion: 2007-11
• Status Verified: 2014-10
• Study First Submitted: 2014-10-06
• Study First Submitted QC: 2014-10-06
• Last Update Submitted: 2014-10-06
• Study First Posted: 2014-10-09
• Last Update Posted: 2014-10-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 30

Inclusion Criteria

1. Healthy males according to the following criteria:

   Based upon a complete medical history, including the physical examination, vital signs (blood pressure, pulse rate and body temperature), 12-lead ECG, clinical laboratory tests, no finding of clinical relevance, no evidence of a clinically relevant concomitant disease

2. Age ≥20 and Age ≤35 years

3. Body weight ≥50 kg

4. BMI ≥17.6 and BMI ≤26.4 kg/m2 (Body Mass Index)

5. Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice

Exclusion Criteria

1. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
2. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
3. Chronic or relevant acute infections
4. Any clinical relevant findings of the laboratory test deviating from normal
5. Positive result for hepatitis B antigen, anti hepatitis C virus anti bodies, syphilitic test or HIV test
6. Surgery of gastrointestinal tract (except appendectomy)
7. History of relevant orthostatic hypotension (mean standing systolic blood pressure (SBP) varies by ≥20 mmHg from mean supine SBP or mean standing diastolic blood pressure (DBP) varies by ≥10 mmHg from mean supine DBP), fainting spells or blackouts
8. History of hepatic dysfunction (e.g. biliary cirrhosis, cholestasis)
9. History of serious renal dysfunction
10. History of bilateral renal artery stenosis or renal artery stenosis in a solitary kidney
11. History of cerebrovascular disorder
12. History of hyperkalemia
13. Known hypersensitivity to any component of the formulation, or to any other angiotensin II receptor blockers, angiotensin converting enzyme or dihydropyridine
14. Intake of drugs with a long half-life (≥24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial
15. Use of drugs which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation within 7 days prior to administration or during the trial
16. Participation in another trial with an investigational drug within 4 months or 6 half-lives of the investigational drug prior to administration
17. Smoker (≥20 cigarettes/day)
18. Alcohol abuse (60 g or more ethanol/day: ex. 3 middle-sized bottles of beer, 3 gous (equivalent to 540 mL) of sake)
19. Drug abuse
20. Blood donation (more than 100 mL within 4 weeks prior to administration or during the trial)
21. Excessive physical activities (within 1 week prior to administration or during the trial)
22. Intake of alcohol within 2 days prior to administration
23. Inability to comply with dietary regimen of study centre
24. Intake of any drugs/supplements with ingredient of hypericum perforatum or citrus fruits (e.g. grapefruits, Sevilla orange) within 5 days prior to administration
25. Inability to refrain from smoking on trial days
26. Any other volunteers whom, the principal investigator or sub investigator would not allow to participate in this study

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Telmisartan/amlodipine fixed-dose combination	Telmisartan/amlodipine fixed-dose combination (FDC) tablet	-
Telmisartan and amlodipine mono-components	Telmisartan	-
Telmisartan and amlodipine mono-components	Amlodipine	-

Primary Outcome Measures

Name	Time	Method
Maximum measured concentration of the analyte in plasma (Cmax)	up to 144 hours after administration of study drug
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz)	up to 144 hours after administration of study drug

Secondary Outcome Measures

Name	Time	Method
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞)	up to 144 hours after administration of study drug
Terminal rate constant of the analyte in plasma (λz)	up to 144 hours after administration of study drug
Time from administration to the maximum concentration of the analyte in plasma (tmax)	up to 144 hours after administration of study drug
Terminal rate constant of the analyte in plasma (t1/2)	up to 144 hours after administration of study drug
Mean residence time of the analyte in the body after po administration (MRTpo)	up to 144 hours after administration of study drug
Number of subjects with adverse events	up to 56 days